An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study

Laurence Klotz,Darrel Drachenberg,R Singal,Armen Aprikian,Y. Fradet,M Kebabdjian,M. Zarenda,Joseph L. Chin

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study

2014

Laurence Klotz
Darrel Drachenberg
R Singal
Armen Aprikian
Y. Fradet
M Kebabdjian
M. Zarenda
Joseph L. Chin

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study

Keywords:

Prostatectomy
Benign prostatic hyperplasia (BPH)
Urology
Prostate-specific antigen
Prostate cancer
Castration Resistance
Prostatitis
Medicine
Bicalutamide
dose escalation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations